K.H. Lee

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Seo‐Young Park, M.-H. Lee, Minjung Seong et al. · Annals of Oncology · 2020 · 192 citations · Full text

Medicine, Oncology, Pharmacology +17

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

Joshua K. Sabari, Catherine A. Shu, K. Park et al. · Journal of Thoracic Oncology · 2021 · 40 citations · Full text

Medicine, Oncology, Pharmacology +16

MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors

B.C. Cho, Robert C. Doebele, Misako Nagasaka et al. · Journal of Thoracic Oncology · 2021 · 35 citations · Full text

Medicine, Cancer Biology, Oncology +12

Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang et al. · Annals of Oncology · 2019 · 34 citations · Full text

Medicine, Oncology, Pharmacology +11

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

M-J. Ahn, S-W. Kim, Laura Rodríguez et al. · Annals of Oncology · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacology +15